where Ai - the value of one out of tested parameters; Amin and Amax - the limits for alterations in laboratory values in healthy persons and patients with acute purulent obstructive pyelonephritis followed by calculating the severity coefficient (SC) by the following formula (2):; where Il - the quantity of leukocytes, Isn - the quantity of segmented neutrophils, Irn - the quantity of rod neutrophils, Iu - urea, Icr - creatinine, Igl - glucose, Iac - ACAT. SC value being equal to 2-6 c. u. is considered to be a norm. At SC being below 9 c. u. patients' state is evaluated to be satisfactory followed by performing generally accepted therapy. At SC being above 10 c. u. -the severe state is concluded. Additional therapy with "Immunophan" immunomodulator is required intramuscularly per 1.0 ml daily for 10 d and "Oliphen" antioxidant intravenously per 2 ml of 7%-solution/400 ml isotonic solution twice daily for 10 d, then perorally per 1 tablet thrice daily for 10 d. The innovation enables to correct the course of pharmacotherapy conducted.;EFFECT: higher accuracy of detection.;2 ex, 1 tbl"/> METHOD FOR INDIVIDUAL MATCHING PHARMACOTHERAPY IN PATIENTS WITH ACUTE PURULENT OBSTRUCTIVE PYELONEPHRITIS WITH METABOLIC X-SYNDROME
首页> 外国专利> METHOD FOR INDIVIDUAL MATCHING PHARMACOTHERAPY IN PATIENTS WITH ACUTE PURULENT OBSTRUCTIVE PYELONEPHRITIS WITH METABOLIC X-SYNDROME

METHOD FOR INDIVIDUAL MATCHING PHARMACOTHERAPY IN PATIENTS WITH ACUTE PURULENT OBSTRUCTIVE PYELONEPHRITIS WITH METABOLIC X-SYNDROME

机译:代谢性X线综合征急性脓肿性梗阻性甲状腺炎患者的个体匹配药物治疗方法

摘要

FIELD: medicine, urology.;SUBSTANCE: the present innovation deals with studying clinical and biochemical blood values by the following formula (1):; where Ai - the value of one out of tested parameters; Amin and Amax - the limits for alterations in laboratory values in healthy persons and patients with acute purulent obstructive pyelonephritis followed by calculating the severity coefficient (SC) by the following formula (2):; where Il - the quantity of leukocytes, Isn - the quantity of segmented neutrophils, Irn - the quantity of rod neutrophils, Iu - urea, Icr - creatinine, Igl - glucose, Iac - ACAT. SC value being equal to 2-6 c. u. is considered to be a norm. At SC being below 9 c. u. patients' state is evaluated to be satisfactory followed by performing generally accepted therapy. At SC being above 10 c. u. -the severe state is concluded. Additional therapy with "Immunophan" immunomodulator is required intramuscularly per 1.0 ml daily for 10 d and "Oliphen" antioxidant intravenously per 2 ml of 7%-solution/400 ml isotonic solution twice daily for 10 d, then perorally per 1 tablet thrice daily for 10 d. The innovation enables to correct the course of pharmacotherapy conducted.;EFFECT: higher accuracy of detection.;2 ex, 1 tbl
机译:领域:本发明通过以下公式(1)研究临床和生化血液价值: 其中A i -测试参数之一的值; A min 和A max -健康人和急性化脓性阻塞性肾盂肾炎患者的实验室值改变的极限,然后通过以下公式计算严重性系数(SC) (2):; 其中I l -白细胞的数量,I sn -分段的中性粒细胞的数量,I rn -杆的数量中性粒细胞,I u -尿素,I cr -肌酐,I gl -葡萄糖,I ac -ACAT。 SC值等于2-6c。你被认为是一种规范。在SC低于9c时。你评估患者的状态是否令人满意,然后进行普遍接受的治疗。在SC高于10 c时。你-严重状态结束。每天每1.0 ml肌注需要10 d的肌内免疫调节剂“ Immunophan”,每天两次每次7%溶液/ 400 ml等渗溶液应每次2 d静脉注射“ Oliphen”抗氧化剂,持续10 d,然后每天每1片口服三次10天这项创新技术可以纠正进行药物治疗的过程。效果:更高的检测准确度; 2 ex,1 tbl

著录项

  • 公开/公告号RU2242758C1

    专利类型

  • 公开/公告日2004-12-20

    原文格式PDF

  • 申请/专利权人

    申请/专利号RU20030110199

  • 申请日2003-04-09

  • 分类号G01N33/48;G01N33/49;

  • 国家 RU

  • 入库时间 2022-08-21 22:02:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号